Conference Proceedings
Daratumumab, Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Based on Prior Treatment Exposure: Updated Efficacy Analysis of Castor
Asher A Chanan-Khan, Suzanne Lentzsch, Hang Quach, Noemi Horvath, Marcelo Capra, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Ming Qi, William Deraedt, Jordan Schecter, Himal Amin, Xiang Qin, Tineke Casneuf, Christopher Chiu, A Kate Sasser, Pieter Sonneveld
Blood | AMER SOC HEMATOLOGY | Published : 2016
Grants
Funding Acknowledgements
Lentzsch: BMS: Consultancy; Foundation One: Consultancy; Celgene: Consultancy, Honoraria. Quach: Celgene: Membership on an entity's Board of Directors or advisory committees; Janssen Cilag: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees. Ovilla: Janssen: Consultancy. Qi: Janssen: Employment. Deraedt: Janssen: Employment, Equity Ownership. Schecter: Janssen: Employment, Equity Ownership. Amin: Janssen: Employment. Qin: Janssen: Employment. Casneuf: Johnson & Johnson: Equity Ownership; Janssen R&D, Beerse, Belgium: Employment. Chiu: Janssen: Employment. Sasser: Johnson & Johnson: Equity Ownership; Janssen Pharmaceuticals R&D: Employment. Sonneveld: Karyopharm: Janssen: Consultancy, Honoraria, Research Funding; Celgene: Honoraria, Research Funding; Takeda: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding.